Nkarta (NASDAQ:NKTX – Free Report) had its target price trimmed by Needham & Company LLC from $13.00 to $11.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.
A number of other equities analysts have also weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 target price for the company. HC Wainwright lowered their price objective on shares of Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Finally, Raymond James raised shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a research note on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $17.17.
View Our Latest Research Report on NKTX
Nkarta Stock Down 2.4 %
Nkarta (NASDAQ:NKTX – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.15. As a group, analysts expect that Nkarta will post -1.92 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Susquehanna Fundamental Investments LLC purchased a new position in Nkarta during the 1st quarter valued at about $788,000. Vanguard Group Inc. increased its position in Nkarta by 26.0% during the 1st quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock valued at $21,255,000 after purchasing an additional 405,753 shares during the period. AQR Capital Management LLC purchased a new position in Nkarta during the 2nd quarter valued at about $938,000. Federated Hermes Inc. increased its position in Nkarta by 28,478.7% during the 2nd quarter. Federated Hermes Inc. now owns 135,749 shares of the company’s stock valued at $802,000 after purchasing an additional 135,274 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Nkarta during the 2nd quarter valued at about $1,489,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.
About Nkarta
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Read More
- Five stocks we like better than Nkarta
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 11/4 – 11/8
- What is the Nikkei 225 index?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.